Results availability from clinical research of female urinary incontinence

Neurourology and Urodynamics

Volumn 31, Issue 1, 2012, Pages 22-29

  Shamliyan, Tatyana A ^a,b   Kane, Robert L ^a,b   Wyman, Jean ^c   Sainfort, Francois ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Minnesota Evidence based Practice Center   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

clinical trials as topic; databases; factual; government regulation; National Library of Medicine (U.S.); outcome assessment (health care); public policy; quality control; registries; urinary incontinence

Indexed keywords

BIOLOGICAL THERAPY; CLINICAL RESEARCH; HUMAN; INTERVENTION STUDY; PEER REVIEW; PUBLISHING; REVIEW; URINE INCONTINENCE;

BIOMEDICAL RESEARCH; FEMALE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PUBLICATIONS; UNITED STATES; URINARY INCONTINENCE;

EID: 84856225728     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21220     Document Type: Review

References (38)

1. Abrams P,. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th edition. Paris: Health Publications Ltd.; 2009. Committee 1 Epidemiology of Urinary (UI) and Fecal (FI) Incontinence and Pelvic Organ Prolapse (POP).
2. Carls C,. The prevalence of stress urinary incontinence in high school and college-age female athletes in the midwest: Implications for education and prevention. Urol Nurs 2007; 27: 21-4, 39.
3. Kinchen KS, Lee J, Fireman B, et al. The prevalence, burden, and treatment of urinary incontinence among women in a managed care plan. J Womens Health (Larchmt) 2007; 16: 415-22.
4. Sampselle CM, Harlow SD, Skurnick J, et al. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol 2002; 100: 1230-8.
5. Boyington JE, Howard DL, Carter-Edwards L, et al. Differences in resident characteristics and prevalence of urinary incontinence in nursing homes in the southeastern United States. Nurs Res 2007; 56: 97-107.
6. Epstein LB, Goldberg RP,. The overactive bladder and quality of life. Int J Fertil Womens Med 2005; 50: 30-6.
7. Bradway C,. Urinary incontinence among older women. Measurement of the effect on health-related quality of life. J Gerontol Nurs 2003; 29: 13-9.
8. Slutsky JR, Clancy CM,. The Agency for Healthcare Research and Quality's Effective Health Care Program: Creating a dynamic system for discovering and reporting what works in health care. Am J Med Qual 2005; 20: 358-60.
9. Slutsky J, Atkins D, Chang S, et al. Comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 2010. 63: 481-3. Epub Oct 1, 2008.
10. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: A comparative study. Urology 2004; 63: 461-5.
11. Subak LL, Brown JS, Kraus SR, et al. The "costs" of urinary incontinence for women. Obstet Gynecol 2006; 107: 908-16.
12. Papanicolaou S, Pons ME, Hampel C, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005; 52: S35-47.
13. Darkow T, Fontes CL, Williamson TE,. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511-9.
14. Bourgeois FT, Murthy S, Mandl KD,. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158-66.
15. Ross JS, Mulvey GK, Hines EM, et al. Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis. PLoS Med 2009; 6: e1000144.
16. Dickersin K, Min YI,. NIH clinical trials and publication bias. Online J Curr Clin Trials 1993; Apr 28; Doc No 50.
17. Dickersin K,. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385-9.
18. World Association of Medical Editors (WAME) Editorial Policy Committee. The Registration of Clinical Trials. Available at; Posted July 22, 2005, accessed September 2011.
19. Food and Drug Administration Amendments Act of 2007. Pub L No 110-85, 121 Stat 823, 904, Title VIII (September 27, 2007), 42 USC 282(j) (Supp 2009), 2010.
20. Chan AW, Laupacis A, Moher D,. Registering results from clinical trials. JAMA 2010; 303: 2138-9, author reply 9.
21. Mancini J, Reynier CJ,. Registering results from clinical trials. JAMA 2010; 303: 2139, author reply.
22. Miller JD,. Registering clinical trial results: The next step. JAMA 2010; 303: 773-4.
23. Tse T, Williams RJ, Zarin DA,. Update on registration of clinical trials in ClinicalTrials.gov. Chest 2009; 136: 304-5.
24. Shamliyan T,. Reporting of results of interventional studies by the information service of the National Institutes of Health. Clin Pharmacol Adv Appl 2010; 2010: 169-76.
25. Higgins J, Green S, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons; 2008.
26. Agency for Healthcare Research, Quality (AHRQ). Methods Guide for Comparative Effectiveness Reviews 2007. [cited 2009 August]. Available from:.
27. Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011; 59: 387-400.
28. Schroder A, Abrams P, Andersson KE, et al. Guidelines on urinary incontinence. 2010. Available at; accessed in September 2011.
29. Abrams P,. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. 4th edition. Paris: Health Publications Ltd; 2009. Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence.
30. Herbison P,. Full publication of abstracts of randomised controlled trials published at International Continence Society meetings. Neurourol Urodyn 2004; 23: 101-3.
31. Shamliyan T, Wyman J, Bliss DZ, et al. Prevention of urinary and fecal incontinence in adults. Evid Rep Technol Assess (Full Rep) 2007; 1-379.
32. HHS. Code of Federal Regulations. TITLE 45 PUBLIC WELFARE Department of Health and Human Services PART 46, 2009.
33. U.S. Food and Drug Administration. Statistical Review for Enablex (Darifenacin Hydrobromide) Extended Release Tablets. 2004. [cited 2010 June 25]; Available from:.
34. U.S. Food and Drug Administration. Medical Review for Enablex (Clarifenacin) Extended Release Tablets. 2004. [cited 2010 June 25]; Available from:.
35. Moher D,. Reporting research results: A moral obligation for all researchers. Can J Anaesth 2007; 54: 331-5.
36. The Office of Research Integrity (ORI). Responsible Conduct of Research (RCR). [cited 2010 June 16]; Available from:.
37. Gafni-Kane A, Bakali E, Botros S, Tincello D, editors. Factors influencing participation research in urogynaecology: Comparison of patients from the USA and UK. Neurourol Urodyn 2010. Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. For the writing.
38. Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database - Update and key issues. N Engl J Med 2011; 364: 852-60.